Table 1.
Patient characteristics
| Group A (N = 69) | Group B (N = 171) | Group C (N = 8666) | P‐value | All (N = 8906) | |
|---|---|---|---|---|---|
| Age | |||||
| <65 | 48 (69.6%) | 101 (59.1%) | 6150 (71.0%) | 0.0032 | 6299 (70.7%) |
| ≥65 | 21 (30.4%) | 70 (40.9%) | 2516 (29.0%) | 2607 (29.3%) | |
| Sex | |||||
| Male | 43 (62.3%) | 98 (57.3%) | 4849 (56.0%) | 0.5375 | 4990 (56.0%) |
| Female | 26 (37.7%) | 73 (42.7%) | 3817 (44.0%) | 3916 (44.0%) | |
| Race | |||||
| White | 60 (87.0%) | 151 (88.3%) | 7481 (86.3%) | 0.4833 | 7692 (86.4%) |
| Black | 6 (8.7%) | 12 (7.0%) | 725 (8.4%) | 743 (8.3%) | |
| Native Hawaiian or other Pacific Islander | 0 (0.0%) | 1 (0.6%) | 37 (0.4%) | 38 (0.4%) | |
| Asian | 2 (2.9%) | 5 (2.9%) | 211 (2.4%) | 218 (2.4%) | |
| American Indian or Alaskan Native | 1 (1.4%) | 0 (0.0%) | 18 (0.2%) | 19 (0.2%) | |
| Mixed | 0 (0.0%) | 1 (0.6%) | 14 (0.2%) | 15 (0.2%) | |
| Unknown | 0 (0.0%) | 1 (0.6%) | 180 (2.1%) | 181 (2.0%) | |
| Race | |||||
| White | 60 (87.0%) | 151 (88.3%) | 7481 (86.3%) | 0.9517 | 7692 (86.4%) |
| Black | 6 (8.7%) | 12 (7.0%) | 725 (8.4%) | 743 (8.3%) | |
| Others | 3 (4.3%) | 8 (4.7%) | 460 (5.3%) | 471 (5.3%) | |
| Body surface area | 0.3414 | ||||
| Median | 1.9 | 1.8 | 1.9 | 1.9 | |
| Range | 0.6–2.4 | 1.3–2.6 | 0.1–3.1 | 0.1–3.1 | |
| Treatment | |||||
| M | 10 (14.5%) | 23 (13.5%) | 1576 (18.2%) | <0.0001 | 1609 (18.1%) |
| C | 13 (18.8%) | 37 (21.6%) | 2314 (26.7%) | 2364 (26.5%) | |
| M + C | 21 (30.4%) | 63 (36.8%) | 1301 (15.0%) | 1385 (15.6%) | |
| M + M | 9 (13.0%) | 18 (10.5%) | 739 (8.5%) | 766 (8.6%) | |
| C + C | 5 (7.2%) | 11 (6.4%) | 767 (8.9%) | 783 (8.8%) | |
| Others | 11 (15.9%) | 19 (11.1%) | 1969 (22.7%) | 1999 (22.4%) | |
| Concurrence of radiation therapy | |||||
| No | 63 (91.3%) | 170 (99.4%) | 8472 (97.8%) | 0.0005 | 8705 (97.7%) |
| Yes | 6 (8.7%) | 1 (0.6%) | 194 (2.2%) | 201 (2.3%) | |
| Previous radiation therapy | |||||
| No | 45 (65.2%) | 114 (66.7%) | 5451 (62.9%) | 0.1394 | 5610 (63.0%) |
| Lung | 2 (2.9%) | 3 (1.8%) | 71 (0.8%) | 76 (0.9%) | |
| Any site in the body except lung | 22 (31.9%) | 54 (31.6%) | 3144 (36.3%) | 3220 (36.2%) | |
| Coexistence of lung disease† | |||||
| No | 65 (94.2%) | 159 (93.0%) | 8427 (97.2%) | 0.0014 | 8651 (97.1%) |
| Yes | 4 (5.8%) | 12 (7.0%) | 239 (2.8%) | 255 (2.9%) | |
| Smoking history | |||||
| No | 67 (97.1%) | 169 (98.8%) | 8558 (98.8%) | 0.4686 | 8794 (98.7%) |
| Ex‐smoker or current smoker | 2 (2.9%) | 2 (1.2%) | 108 (1.2%) | 112 (1.3%) | |
| Coexistence of lung lesion‡ | |||||
| No | 48 (69.6%) | 122 (71.3%) | 5993 (69.2%) | 0.8263 | 6163 (69.2%) |
| Yes | 21 (30.4%) | 49 (28.7%) | 2673 (30.8%) | 2743 (30.8%) | |
| ECOG‐PS | |||||
| 0 | 15 (21.7%) | 63 (36.8%) | 2895 (33.4%) | 0.2073 | 2973 (33.4%) |
| 1 | 48 (69.6%) | 93 (54.4%) | 5128 (59.2%) | 5269 (59.2%) | |
| ≥2 | 6 (8.7%) | 15 (8.8%) | 643 (7.4%) | 664 (7.5%) | |
| ECOG‐PS | |||||
| 0 | 15 (21.7%) | 63 (36.8%) | 2895 (33.4%) | 0.077 | 2973 (33.4%) |
| ≥1 | 54 (78.3%) | 108 (63.2%) | 5771 (66.6%) | 5933 (66.6%) | |
| Solid or hematological malignancy | |||||
| Solid tumor | 46 (66.7%) | 95 (55.6%) | 7399 (85.4%) | <0.0001 | 7540 (84.7%) |
| Hematology | 23 (33.3%) | 76 (44.4%) | 1267 (14.6%) | 1366 (15.3%) | |
| LDH | 0.0604 | ||||
| Median | 284 | 305 | 248 | 249 | |
| Range | 95.0–1611.0 | 80.0–3993.0 | 0.0–17 945.0 | 0.0–17 945.0 | |
| LDH | |||||
| Normal | 32 (46.4%) | 74 (43.3%) | 4297 (49.6%) | 0.2309 | 4403 (49.4%) |
| Elevated | 37 (53.6%) | 97 (56.7%) | 4369 (50.4%) | 4503 (50.6%) | |
†Coexistence of pulmonary disease was defined as patient with lung complication or past‐history such as chronic pulmonary lung disease, bronchial asthma, pulmonary embolism, sarcoidosis, pneumothorax, asbestosis and infection. ‡Coexistence of lung lesion was defined as patient with primary lung tumor and/or lung metastases. C, Cytotoxic agent; ECOG; Eastern Cooperation Oncology Group; LDH, lactate dehydrogenase; M, molecularly targeted agent; PS, performance status.